Loading stock data…
AUTL
$1.47+0.06 (+4.26%)
Market ClosedLast close May 1
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Autolus Therapeutics plc in the Healthcare sector is trading at $1.47. The stock is currently 46% below its 52-week high of $2.70, remaining 8.7% below its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why AUTL maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.47
Potential Upside
5%
Whystock Fair Value$1.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$425.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-161.42%
Volume
Today's trading volume
821,150
Recent News
Is Autolus Therapeutics (AUTL) One of the Best Biotech Penny Stocks to Buy in 2026?
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the best biotech penny stocks to buy in 2026. On March 27, Autolus Therapeutics reported Q4 and full-year 2025 financial results, highlighting the commercial scale-up of its CAR T-cell therapy, AUCATZYL. The company achieved net product revenue of $74.3 million for 2025, with $23.3 million generated in Q4. […]
European Equities Traded in the US as American Depositary Receipts Decline Tuesday
European equities traded in the US as American depositary receipts were lower on Tuesday morning, do
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
European equities traded in the US as American depositary receipts were trending lower late Monday m
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
European equities traded in the US as American depositary receipts were rising late Friday morning,
How The Autolus Therapeutics (AUTL) Narrative Is Shifting With Recalibrated Targets And Fair Value
Autolus Therapeutics has seen its modeled fair value move from US$8.79 to US$8.81, a very modest adjustment that still matters for anyone tracking the stock’s valuation story. Recent Street research links this shift to refreshed price target work, as analysts reassess discount rates, revenue trajectories, and risk around execution before resetting where they see upside and downside for the shares. As you read on, you will see how this evolving narrative can help you stay aligned with what...